Last reviewed · How we verify

GBS trivalent vaccine

GlaxoSmithKline · Phase 2 active Biologic

Stimulates the immune system to produce antibodies against the influenza virus, RSV, and Hib.

Stimulates the immune system to produce antibodies against the influenza virus, RSV, and Hib. Used for Influenza, RSV infection, Hib infection.

At a glance

Generic nameGBS trivalent vaccine
SponsorGlaxoSmithKline
Drug classInfluenza vaccine, RSV vaccine, Hib vaccine
ModalityBiologic
Therapeutic areaVaccines
PhasePhase 2

Mechanism of action

The GBS trivalent vaccine works by introducing inactivated influenza virus, RSV, and Hib antigens to the body, which triggers an immune response and the production of antibodies to fight these pathogens.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: